C WorldWide Group’s Syndax Pharmaceuticals SNDX Stock Holding History

C WorldWide Group’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-12,896	Closed	-$57K	–	124
2018 Q4	$57K	Sell	12,896 -331	-3%	-$1.81K	﹤0.01%	122
2018 Q3	$107K	Buy	13,227 +2,074	+19%	+$14.8K	﹤0.01%	131
2018 Q2	$78K	Hold	11,153	–	–	﹤0.01%	130
2018 Q1	$159K	Sell	11,153 -347	-3%	-$3.68K	﹤0.01%	121
2017 Q4	$101K	Sell	11,500 -1,800	-14%	-$17.8K	﹤0.01%	122
2017 Q3	$156K	Buy	13,300 +2,200	+20%	+$27K	﹤0.01%	125
2017 Q2	$155K	Sell	11,100 -800	-7%	-$9.14K	﹤0.01%	124
2017 Q1	$163K	Buy	+11,900	New	+$124K	﹤0.01%	123

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

C WorldWide Group's SNDX Position: Q1 2019 in Review

C WorldWide Group sold out of Syndax Pharmaceuticals (SNDX) in Q1 2019, closing a stake of 12,896 shares — an estimated $57K sold.

C WorldWide Group first reported a position in SNDX in Q1 2017 and held it in 8 quarters. The position peaked at $163K in Q1 2017. 69 funds tracked by Wall St. Rank hold SNDX as of Q1 2019.

C WorldWide Group reported no remaining Syndax Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
C WorldWide Group sold 12,896 Syndax Pharmaceuticals shares in Q1 2019, an estimated $57K.
C WorldWide Group first reported a position in Syndax Pharmaceuticals in Q1 2017 and held it in 8 quarters.
C WorldWide Group's Syndax Pharmaceuticals position peaked at $163K in Q1 2017.
69 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2019.

Based on C WorldWide Group's 13F filing for Q1 2019, filed 3 May 2019.